A Trial of ONO-2808 in Participants With the Parkinsonian Subtype of Multiple System Atrophy (MSA-P)

Brief summary

The main goal of this clinical trial is to learn if ONO-2808 works to treat adults with the Parkinsonian subtype of Multiple System Atrophy (MSA-P). Researchers will compare ONO-2808 to a placebo (a look-alike substance that contains no drug) to see if ONO-2808 works to treat MSA-P. Participants will: * Take ONO-2808 or placebo orally for up to 48 weeks * Make visits to the clinic for checkups and tests * Answer questions about their health throughout the trial.

Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.

Trial details

status

NOT_YET_RECRUITING

phase

PHASE3

study type

INTERVENTIONAL

enrollment

486

sponsor

Ono Pharmaceutical Co., Ltd.

conditions

Multiple System Atrophy, Parkinson Variant

interventions

DRUG: ONO-2808; OTHER: Placebo

start date

2027-01-01

start date type

ESTIMATED

primary completion date

2029-10-01

has results

false

data source

ClinicalTrials.gov

data processed

2026-10-29T09:00:05

modifications

selected fields only; whitespace normalized; brief summary truncated to 2,000 characters